Skip to main content
SpringerLink
Log in

Benefits of tamoxifen treatment in women with breast cancer outweigh the risks of developing endometrial cancer

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. IARC Monograph conclusion on tamoxifen. Lancet 1996 Mar 2; 347: 605

    Google Scholar 

  2. Tamoxifen labeled carcinogen. Science 1996 Mar 8; 271: 1367

    Article  Google Scholar 

  3. Tamoxifen and endometrial cancer. Am Fam Physican 1996 Jun; 53(8): 2758

    Google Scholar 

  4. Court C. International group evaluates tamoxifen risks for women. Br Med J 1996 Mar 2; 312: 529

    Article  CAS  Google Scholar 

  5. Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women: a safety perspective. Drugs & Aging 1996 May; 8(5): 329–37

    Article  CAS  Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992 Jan 11; 339: 71–85

    Google Scholar 

  7. Rutqvist LE, Johansson H, Signomklao T. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Nat Cancer Inst 1995 May 3; 87: 645–51

    Article  PubMed  CAS  Google Scholar 

  8. Sasco AJ. Tamoxifen and menopausal status: risks and benefits. Lancet 1996 Mar 16; 347: 761

    Article  PubMed  CAS  Google Scholar 

  9. Jordan VC. Is tamoxifen-stimulated endometrial cancer a valid cause célèbre? Cancer Invest 1996 Jan; 14 (Suppl. 1): 44

    Google Scholar 

  10. Cohen I, Beyth Y, Tepper R, et al. Time dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic postmenopausal breast cancer patients. Br J Obstet Gynaecol 1996 Jun; 103: 589

    Google Scholar 

  11. Cuenca RE, Giachino J, Arredondo MA, et al. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer 1996 May 15; 77: 2058–63

    Article  PubMed  CAS  Google Scholar 

  12. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Nat Cancer Inst 1993 Nov 17; 85: 1850–5

    Article  PubMed  CAS  Google Scholar 

  13. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11(3): 485–90

    PubMed  CAS  Google Scholar 

  14. Veronesi U. Prevention of breast cancer with tamoxifen: the Italian study in hysterectomized women. Breast 1995 Dec; 4: 267–72

    Article  Google Scholar 

  15. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513–29

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benefits of tamoxifen treatment in women with breast cancer outweigh the risks of developing endometrial cancer. Drugs Ther. Perspect 8, 11–13 (1996). https://doi.org/10.2165/00042310-199608100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608100-00004

Search

Navigation